Gossamer Bio vs Keros Therapeutics
GOSS and KROS side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How GOSS and KROS compare
Gossamer Bio is the larger company, worth 24 times as much as Keros Therapeutics ($5.4B against $224M).
Gossamer Bio grew revenue faster over the last twelve months (32.4% versus −93.7% for Keros Therapeutics).
Gossamer Bio keeps more of each dollar of sales as profit, with a net margin of −235% compared with −572% at Keros Therapeutics.
Keros Therapeutics scores higher on the StockData Score (7 against 1 for Gossamer Bio), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | GOSS | KROS |
|---|---|---|
| Size and price | ||
| Market cap | $5.4B | $224M |
| Share price | $11.04 | $11.31 |
| Change, 1 year | −94.9% | −34.5% |
| Change, 5 years | −98.7% | −79.8% |
| Beta (5Y) | 2.33 | 2.04 |
| Employees | 161 | 78 |
| StockData Score | ||
| Total score | 1 | 7 (better) |
| Valuation score | 0 | 1 (better) |
| Growth score | 1 (better) | 0 |
| Performance score | 0 | 1 (better) |
| Health score | 0 | 5 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 101× | 15.4× (better) |
| P/B | – | 0.9× |
| FCF yield | −3.0% (better) | −21.6% |
| Growth | ||
| Revenue growth (TTM) | 32.4% (better) | −93.7% |
| Net income growth (TTM) | – | −543% |
| EPS growth (TTM) | – | −1287% |
| Profitability | ||
| Operating margin | −312% (better) | −698% |
| Net margin | −235% (better) | −572% |
| FCF margin | −305% (better) | −334% |
| Return on equity | – | −17.2% |
| Return on invested capital | – | −755% |
| Financial health | ||
| Debt / equity | – | 0.00 |
| Interest coverage | −15.2× | – |
| Current ratio | 0.53 | 21.96 (better) |
| Altman Z-score | −15.26 | 2.67 (better) |
| Piotroski F-score | 1 | 6 (better) |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 0.98% | 101% |
| Held by insiders | 2.8% | 53.3% |
| Insider net buying, 12 months | – | −$453K |
| Superinvestors holding | 1 | – |
| Short interest, % of float | 0.28% | 11.7% |
Go deeper
- GOSS stock overview
- GOSS income statement
- GOSS valuation and score
- KROS stock overview
- KROS income statement
- KROS valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.